Sara Tolaney, MD, MPH

home / authors / sara-tolaney-md-mph

Articles

Overview of TROPiCS-02 Study of Sacituzumab Govitecan in HR+/HER2- mBC

July 23rd 2023

Sara Tolaney, MD, MPH, discusses sacituzumab govitecan-hziy as an effective and safe treatment for patients with hormone receptor-positive/HER2-negative metastatic breast cancer.

Final OS Analysis Shows Benefit of Sacituzumab Govitecan in HR+/HER2- mBC

Sara Tolaney, MD, MPH

June 5th 2023

Sara Tolaney, MD, MPH, discusses sacituzumab govitecan-hziy as an effective and safe treatment for patients with hormone receptor-positive/HER2-negative metastatic breast cancer.

A Study Investigating Pembrolizumab in Combination With Eribulin in TNBC

Sara Tolaney, MD, MPH

January 3rd 2017

Sara Tolaney, MD, MPH, associate clinical research director of Breast Oncology at the Dana-Farber Cancer Institute in Boston, discusses a clinical trial investigating pembrolizumab in combination with eribulin in triple-negative breast cancer. 